Top

International Journal of Clinical Oncology

Published in:

01-04-2018 | Original Article

Esophageal squamous cell neoplasia is an independent negative prognostic factor for head and neck cancer patients

Authors: Yasuhiko Hamada, Toshiro Mizuno, Kyosuke Tanaka, Masaki Katsurahara, Noriyuki Horiki, Reiko Yamada, Hiroyuki Inoue, Yoshiyuki Takei, Naoyuki Katayama

Published in: International Journal of Clinical Oncology | Issue 2/2018

Abstract

Background

Patients with head and neck cancer (HNC) have a high incidence of esophageal squamous cell neoplasms (ESCN). ESCN also has a negative impact on the survival of HNC patients. However, recent endoscopic advances enable the early detection of ESCN, and novel treatments may lead to improving survival rates for HNC patients with ESCN.

Methods

HNC patients who underwent magnifying esophagogastroduodenoscopy (EGDS) from 2005 to 2012 were included in this study (n = 226). We analyzed the prevalence and prognostic value of ESCN in HNC patients and the difference in overall survival between HNC patients with and without ESCN.

Results

Thirty-four patients (15%) developed an ESCN during their clinical course. Of the 34 patients, 10 patients underwent endoscopic resection for ESCN and 10 patients underwent simultaneous chemoradiation therapy for HNC and ESCN. The 3-year survival rates in HNC patients with and without ESCN were 53% and 70%, respectively. Multivariate analysis identified the advanced clinical stage of the HNC [hazard ratio (HR) = 2.15; 95% confidence interval (CI) = 1.18–3.93; p = 0.012] and the presence of ESCN (HR = 1.73; 95% CI = 1.00–2.97; p = 0.049) as significant and independent determinants of overall survival.

Conclusions

Our study suggests that although the survival of HNC patients with ESCN may be improved by routine EGDS during tumor surveys and by advances in endoscopy, the presence of ESCN still remains an independent negative prognostic factor for HNC patients.

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed

Chuang SC, Scelo G, Tonita JM et al (2008) Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 123:2390–2396CrossRefPubMed

Schwartz LH, Ozsahin M, Zhang GN et al (1994) Synchronous and metachronous head and neck carcinomas. Cancer (Phila) 74:1933–1938CrossRef

Bongers V, Braakhuis BJ, Tobi H et al (1996) The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer. Cancer Epidemiol Biomark Prev 5:595–598

Johnson N (2001) Tobacco use and oral cancer: a global perspective. J Dent Educ 65:328–339PubMed

Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (Phila) 6:963–968CrossRef

Haughey BH, Gates GA, Arfken CL et al (1992) Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 101:105–112CrossRefPubMed

Muto M, Hironaka S, Nakane M et al (2002) Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 56:517–521CrossRefPubMed

Su YY, Chen WC, Chuang HC et al (2013) Effect of routine esophageal screening in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 139:350–354CrossRefPubMed

10.

Wang WL, Lee CT, Lee YC et al (2011) Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer. Head Neck 33:77–81CrossRefPubMed

11.

Hung SH, Tsai MC, Liu TC et al (2013) Routine endoscopy for esophageal cancer is suggestive for patients with oral, oropharyngeal and hypopharyngeal cancer. PLoS One 8:e72097CrossRefPubMedPubMedCentral

12.

Chen MC, Huang WC, Chan CH et al (2010) Impact of second primary esophageal or lung cancer on survival of patients with head and neck cancer. Oral Oncol 46:249–254CrossRefPubMed

13.

León X, Quer M, Diez S et al (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21:204–210CrossRefPubMed

14.

Chu PY, Chang SY, Huang JL et al (2010) Different patterns of second primary malignancy in patients with squamous cell carcinoma of larynx and hypopharynx. Am J Otolaryngol 31:168–174CrossRefPubMed

15.

Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley, Hoboken

16.

Uedo N, Fujishiro M, Goda K et al (2011) Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. Dig Endosc 23:58–71CrossRefPubMed

17.

Lee CT, Chang CY, Lee YC et al (2010) Narrow-band imaging with magnifying endoscopy for the screening of esophageal cancer in patients with primary head and neck cancers. Endoscopy 42:613–619CrossRefPubMed

18.

Lim H, Kim DH, Jung HY et al (2015) Clinical significance of early detection of esophageal cancer in patients with head and neck cancer. Gut Liver 9:159–165CrossRefPubMed

19.

Cooper JS, Porter K, Mallin K et al (2009) National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 31:748–758CrossRefPubMed

20.

Guillot T, Spielmann M, Kac J et al (1992) Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas. Laryngoscope 102:311–319CrossRefPubMed

21.

Nguyen TD, Panis X, Legros M et al (1989) Neoadjuvant chemotherapy and irradiation in multiple synchronous squamous cell carcinoma of the upper aerodigestive tract. Radiother Oncol 16:283–288CrossRefPubMed

22.

Welz S, Schmid A, Hehr T et al (2005) Treatment-outcome for synchronous head-and-neck and oesophageal squamous cell carcinoma. Radiother Oncol 77:267–270CrossRefPubMed

23.

Shinoto M, Shioyama Y et al (2011) Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. Am J Clin Oncol 34:362–366CrossRefPubMed

24.

Schallenkamp JM, Miller RC, Brinkmann DH et al (2007) Incidence of radiation pneumonitis after thoracic irradiation: dose–volume correlates. Int J Radiat Oncol Biol Phys 67:410–416CrossRefPubMed

25.

Vogelius IR, Bentzen SM (2012) A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51:975–983CrossRefPubMedPubMedCentral

Title: Esophageal squamous cell neoplasia is an independent negative prognostic factor for head and neck cancer patients
Authors: Yasuhiko Hamada
Toshiro Mizuno
Kyosuke Tanaka
Masaki Katsurahara
Noriyuki Horiki
Reiko Yamada
Hiroyuki Inoue
Yoshiyuki Takei
Naoyuki Katayama
Publication date: 01-04-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1201-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma

Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics

Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment

Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer